학술논문
Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
Document Type
article
Author
Juan José Alegre-Sancho; Victoria Núñez-Monje; Cristina Campos-Fernández; Isabel Balaguer-Trull; Montserrat Robustillo-Villarino; Marta Aguilar-Zamora; Marta Garijo-Bufort; Teresa Pedraz-Penalva; Carolina Peña-González; Isabel de la Morena; Diego Bedoya-Sanchís; Liliya Yankova-Komsalova; Arantxa Conesa-Mateos; Anna Martinez-Cristóbal; Francisco Javier Navarro-Blasco; Jose Miguel Senabre-Gallego; Francisca Sivera
Source
Frontiers in Medicine, Vol 10 (2023)
Subject
Language
English
ISSN
2296-858X
Abstract
IntroductionPsoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinumab, a biologic disease-modifying antirheumatic drug (bDMARD), has extensive clinical evidence of efficacy and safety in the treatment of PsA but data in clinical practice are still limited. This study aims to provide real-world evidence on secukinumab use, effectiveness, and persistence in PsA.MethodsA retrospective, multicenter study was conducted on patients diagnosed with PsA and treated with secukinumab up to June 2021 at 12 centers in the Valencian Community (Spain). Data on DAS28-CRP, DAPSA, Tender and Swollen Joint Counts (TJC, SJC), enthesitis, dactylitis, skin and nail involvement, pain, patient and physician global assessment (ptGA, phGA) using 100-mm visual analog scale (VAS), and persistence for up to 24 months were collected.ResultsA total of 178 patients were included (49% men; mean [standard deviation, SD] age: 51.4 [10.5] years; 39% obese). Secukinumab was used as a first-, second-, or ≥ third-line bDMARD in 37, 21, and 42% of patients, respectively. The percentage of patients achieving at least low disease activity (DAS28-CRP ≤ 3.2) increased from 25% at baseline to 66% at month 6 (M6) and was maintained (75%) up to M24. Mean (SD) DAS28-CRP baseline values (3.9 [1.2]) decreased to 2.9 (1.1) (p